Second-Generation Antipsychotic Monotherapy Contributes to the Discontinuation of Anticholinergic Drugs in Hospitalized Patients With Schizophrenia

J Clin Psychopharmacol. 2022 Nov-Dec;42(6):591-593. doi: 10.1097/JCP.0000000000001604. Epub 2022 Oct 3.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antipsychotic Agents* / adverse effects
  • Cholinergic Antagonists / adverse effects
  • Humans
  • Schizophrenia* / drug therapy

Substances

  • Antipsychotic Agents
  • Cholinergic Antagonists